Thus, high-grade glioma cells may elude the p16 cell cycle checkpoint either via the homozygous deletion of CDKN2A or via the EZH2-mediated transcriptional knockout of p16 protein secretion which means that loss of p16 protein secretion augments proliferative activity (Table 1) [12]. Here, CDKN2A is linked to central nervous system cancer.